Infigratinib
Infigratinib is an oral targeted therapy known as an FGFR (fibroblast growth factor receptor) inhibitor used to treat certain cancers with specific genetic alterations. It works by blocking FGFR enzymes that drive tumor growth in cancers with FGFR alterations. It is primarily used in patients with advanced or metastatic cholangiocarcinoma who have FGFR2 gene fusions or rearrangements and have received prior treatment.
Infigratinib is an oral FGFR inhibitor used to treat FGFR-altered cholangiocarcinoma and other FGFR-mutated cancers.
Key facts at a glance
- ATC
- L01EN03
- RxNorm
- 2550729
- Generic
- Infigratinib
- Class
- atc-l01
- Brands
- Truseltiq
- Availability
- rx
- Lactation
- unknown
- Routes
- oral
- Forms
- capsule
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
FDA-approved for treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements. May also be used in clinical trials or off-label for other advanced solid tumors with FGFR genetic alterations.
Infigratinib is a small molecule tyrosine kinase inhibitor that selectively blocks FGFR1, FGFR2, and FGFR3 enzymes. By inhibiting these receptors, it interrupts signaling pathways that promote cancer cell growth, survival, and proliferation in tumors with FGFR alterations.
Common side effects include hyperphosphatemia, nail changes, stomatitis, and fatigue. Requires monitoring of phosphate levels and liver function. May cause ocular toxicity including retinal pigment epithelial detachment. Contraindicated in pregnancy due to fetal harm. Patients should be assessed for FGFR alterations before treatment initiation.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy